A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

(2015) Adam C. Kaufman et al.   ANNALS OF NEUROLOGY

Fyn kinase inhibition as a novel therapy for Alzheimer’s disease

(2014) Haakon B Nygaard et al.   Alzheimers Research & Therapy

Current and Emerging Therapies for Alzheimer’s Disease

(2013) Haakon B. Nygaard   CLINICAL THERAPEUTICS

Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein

(2013) Ji Won Um et al.   NEURON

Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study

(2012) Rosemary A. Hannon et al.   BONE

The Complex PrPc-Fyn Couples Human Oligomeric A  with Pathological Tau Changes in Alzheimer's Disease

(2012) M. Larson et al.   JOURNAL OF NEUROSCIENCE

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons

(2012) Ji Won Um et al.   NATURE NEUROSCIENCE

A  neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors

(2012) H. You et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication

(2011) Ulrike K Resenberger et al.   EMBO JOURNAL

Cellular prion protein is essential for oligomeric amyloid- -induced neuronal cell death

(2011) W. Kudo et al.   HUMAN MOLECULAR GENETICS

Amyloid-β-induced Synapse Damage Is Mediated via Cross-linkage of Cellular Prion Proteins

(2011) Clive Bate et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain

(2011) Wen-Quan Zou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A  Inhibition of Ionic Conductance in Mouse Basal Forebrain Neurons Is Dependent upon the Cellular Prion Protein PrPC

(2011) K. Alier et al.   JOURNAL OF NEUROSCIENCE

Alzheimer's Disease Brain-Derived Amyloid- -Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein

(2011) A. E. Barry et al.   JOURNAL OF NEUROSCIENCE

Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia

(2011) Jennifer E. Podesta et al.   LEUKEMIA RESEARCH

Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites

(2011) Darragh B. Freir et al.   Nature Communications

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

(2011) François Piette et al.   Alzheimers Research & Therapy

Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse

(2010) Erika Chung et al.   BMC NEUROSCIENCE

Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: A report from the BINGO study

(2010) Yuichi Ishikawa et al.   CANCER SCIENCE

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

(2010) J. Baselga et al.   CLINICAL CANCER RESEARCH

Prion protein and Aβ-related synaptic toxicity impairment

(2010) Anna Maria Calella et al.   EMBO Molecular Medicine

Interaction between Human Prion Protein and Amyloid-β (Aβ) Oligomers

(2010) Shugui Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein

(2010) D. A. Gimbel et al.   JOURNAL OF NEUROSCIENCE

Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative

(2010) Kewei Chen et al.   NEUROIMAGE

Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy

(2010) K. Bhaskar et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Synthetic amyloid-  oligomers impair long-term memory independently of cellular prion protein

(2010) C. Balducci et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

(2009) Rosemary A Hannon et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Picomolar Amyloid-  Positively Modulates Synaptic Plasticity and Memory in Hippocampus

(2009) D. Puzzo et al.   JOURNAL OF NEUROSCIENCE

 -Amyloid Monomers Are Neuroprotective

(2009) M. L. Giuffrida et al.   JOURNAL OF NEUROSCIENCE

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

(2009) Tim P. Green et al.   Molecular Oncology

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

(2009) Juha Laurén et al.   NATURE